Synthesis-to-Clinic®: integrating isotopic labeling and human ADME to reduce time to clinic
Pharmaceutical Technology
NOVEMBER 24, 2022
We talked to Iain Shaw, Senior Director of 14 C Enabled Drug Development, and Eleanor Row, Executive Director of Commercial, at Quotient Sciences, a drug development and manufacturing accelerator. How does your unique Synthesis-to-Clinic® offering streamline the drug development process?
Let's personalize your content